Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 safety and efficacy study of CTX001 in transfusion-dependent beta-thalassemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Hemoglobinopathies
• Thalassemia

Drugs mentioned

• CTX001

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Beta-Thalassemia, Thalassemia | Phase 2, Phase 3 | Status: COMPLETED